In the BioHarmony Drug Report Database

"Preview" Icon

Filgrastim

Neupogen (filgrastim) is a protein pharmaceutical. Filgrastim was first approved as Neupogen on 1991-02-20. It is used to treat neutropenia in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, neoplasms, and neutropenia. It is known to target macrophage colony-stimulating factor 1 receptor and granulocyte colony-stimulating factor receptor.

 

Trade Name

 

Neupogen
 

Common Name

 

filgrastim
 

ChEMBL ID

 

CHEMBL1201567
 

Indication

 

hematopoietic stem cell transplantation, neoplasms, neutropenia
 

Drug Class

 

Colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF)

Image (chem structure or protein)

Filgrastim structure rendering